Drug Trial Radar · NCT04103892
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Sep 5, 2019
Primary completion
Sep 21, 2022
Study completion Oct 5, 2022
Sponsor
- Lead sponsor
- Clexio Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy. The objective of the study is to assess CLE-100 for the treatment of MDD in participants currently treated with standard antidepressant therapy.
Conditions
- Adjunctive Treatment of Major Depressive Disorder
Interventions
CLE-100Drug
1 tablet of CLE-100 administered once daily
placeboDrug
1 tablet of placebo administered once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) ScoreTime frame: 29 days
Locations
46 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Site 126
Bentonville, Arkansas
Clinical Site 120
Little Rock, Arkansas
Clinical Site 129
Little Rock, Arkansas
Clinical Site 141
Anaheim, California
Clinical Site 115
Bellflower, California
Clinical Site 132
Lafayette, California
Clinical Site 117
Oakland, California
Clinical Site 113
Oceanside, California
Clinical Site 123
Riverside, California
Clinical Site 124
Santa Ana, California
Clinical Site 142
Santa Rosa, California
Clinical Site 112
Torrance, California
Clinical Site 145
Denver, Colorado
Clinical Site 107
Hialeah, Florida
Clinical Site 116
Miami, Florida
Clinical Site 108
Miami Gardens, Florida
Clinical Site 105
Orlando, Florida
Clinical Site 137
Orlando, Florida
Clinical Site 140
Atlanta, Georgia
Clinical Site 104
Decatur, Georgia
Clinical Site 122
Marietta, Georgia
Clinical Site 131
Baltimore, Maryland
Clinical Site 136
Rockville, Maryland
Clinical Site 103
Boston, Massachusetts
Clinical Site 121
Boston, Massachusetts
Clinical Site 151
Dearborn Heights, Michigan
Clinical Site 139
St Louis, Missouri
Clinical Site 125
Lincoln, Nebraska
Clinical Site 110
Las Vegas, Nevada
Clinical Site 101
Marlton, New Jersey
Clinical Site 148
Toms River, New Jersey
Clinical Site 128
New York, New York
Clinical Site 102
Staten Island, New York
Clinical Site 111
Hickory, North Carolina
Clinical Site 143
Raleigh, North Carolina
Clinical Site 138
Middleburg Heights, Ohio
Clinical Site 127
North Canton, Ohio
Clinical Site 106
Media, Pennsylvania
Clinical Site 118
Philadelphia, Pennsylvania
Clinical Site 114
Fort Worth, Texas
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.